美东时间8月19日盘前,一则临床消息搅动整个美股生物医药板块——Moderna(莫德纳)与默沙东对外公布INTerpath-001Ⅲ期临床试验核心结果。双方联合开发的个性化mRNA癌症疫苗intismeran autogene,搭配K药(Keytruda),在1137名已经完成手术切除的高危IIB-IV期黑色素瘤受试者身上,同时拿下主要终点无复发生存期(RFS),以及关键次要终点无远处转移生存期(...
Source Link美东时间8月19日盘前,一则临床消息搅动整个美股生物医药板块——Moderna(莫德纳)与默沙东对外公布INTerpath-001Ⅲ期临床试验核心结果。双方联合开发的个性化mRNA癌症疫苗intismeran autogene,搭配K药(Keytruda),在1137名已经完成手术切除的高危IIB-IV期黑色素瘤受试者身上,同时拿下主要终点无复发生存期(RFS),以及关键次要终点无远处转移生存期(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.